-
- Maryam Sanjadi
- Department of Biochemistry Islamic Azad University Falavarjan Branch Tehran Iran
-
- Ziba Rezvanie Sichanie
- Department of Biochemistry Islamic Azad University Falavarjan Branch Tehran Iran
-
- Hamidreza Totonchi
- Department of Biochemistry Medical School Shahid Beheshti University of Medical Sciences Tehran Iran
-
- Jafar Karami
- Department of Immunology School of Medicine Iran University of Medical Sciences Tehran Iran
-
- Ramazan Rezaei
- Department of Immunology Medical School Shahid Beheshti University of Medical Sciences Tehran Iran
-
- Saeed Aslani
- Rheumatology Research Center Tehran University of Medical Sciences Tehran Iran
説明
<jats:title>Abstract</jats:title><jats:p>Atherosclerosis is regarded as one of the leading causes of mortality and morbidity in the world. Nowadays, it seems that atherosclerosis cannot be defined merely through the Framingham traditional risk factors and that autoimmunity settings exert a remarkable role in its mechanobiology. Individuals with autoimmune disorders show enhanced occurrence of cardiovascular complications and subclinical atherosclerosis. The mechanisms underlying the atherosclerosis in disorders like rheumatoid arthritis, systemic lupus erythematosus, antiphospholipid syndrome, systemic sclerosis and Sjögren's syndrome, seem to be the classical risk factors. However, chronic inflammatory processes and abnormal immune function may also be involved in atherosclerosis development. Autoantigens, autoantibodies, infectious agents and pro‐inflammatory mediators exert a role in that process. Being armed with the mechanisms underlying autoimmunity in the etiopathogenesis of atherosclerosis in rheumatic autoimmune disorders and the shared etiologic pathway may result in substantial developing therapeutics for these patients.</jats:p>
収録刊行物
-
- International Journal of Rheumatic Diseases
-
International Journal of Rheumatic Diseases 21 (5), 908-921, 2018-04-19
Wiley
